ACTRIMS-ECTRIMS: Program at a Glance
Download the MSVirtual2020 Program at a Glance schedule (PDF)
Read More
Meeting Coverage
ESC: Pharmacologic Treatments for Heart Failure Abound, But Uptake Lags
As researchers tout outcomes, Rx lags and a new drug is on the horizon It’s been six years...
Read More
ESC 2020: HFpEF Again Proves to Be Treatment-Resistant
PARALLAX finds biomarker benefit for ARNI, but fails to show functional benefit Heart failure with...
Read More
Patients Let Cardiac, Neuro Care Needs Slide During Pandemic
U.S. and U.K. researchers report dip in services, including TIA admissions Since the Covid-19...
Read More
ESC 2020: Early Is Better for Rhythm Control in Afib
EAST-AFNET 4 findings suggest optimum treatment window is measured in months In medicine, results...
Read More
ESC 2020: EMPEROR-Reduced Trial: Empagliflozin Reduces CV Death by 25%
Findings confirm DAPA-HF ’no fluke’ Adding empagliflozin to standard heart failure treatment...
Read More
ESC 2020: Lowering Blood Pressure Appears to Benefit Most People
Even normotensive people can reduce risks Patients with heart disease or who are at risk of...
Read More
Conference Highlights: AAIC 2020
New research was presented at AAIC 2020, the virtual Alzheimer’s Association International...
Read More
Conference Highlights: ATS 2020 Virtual
New research was presented at ATS 2020 Virtual, the online annual American Thoracic Society...
Read More
Conference Highlights: AAIC 2020
New research was presented at AAIC 2020, the virtual Alzheimer’s Association International...
Read More
ASCO 2020 Virtual Annual Meeting, Lung Cancer
[flippingbook width=”740px” height=”480px” title=”ASCO Lung Cancer...
Read More
Chemoimmunotherapy: Efficacy Among Small Cell Lung Cancer Patients
“The overall take home message from the Virtual ASCO Annual Meeting this year is that...
Read More
Conference Highlights – AIDS 2020: Virtual – A Focus on COVID-19
New research was presented at AIDS 2020: Virtual, the 23rd International AIDS Conference, from...
Read More
ASCO 2020: Atezolizumab with SABR May Be Feasible for Early State NSCLC
Phase 1 trial shows feasibility and safety of neoadjuvant and adjuvant atezolizumab with...
Read More
Phase III ADAURA Trial: Practice Changing Results for NSCLC
Adjuvant osimertinib demonstrated a statistically significant and clinically meaningful benefit...
Read More
New Immunotherapy Treatment Promising for NSCLC
A new type of immunotherapy treatment for metastatic non-small cell lung cancer (NSCLC) is being...
Read More
CASPIAN Trial Update: Phase 3 Results & Perspectives
Updated findings from the phase 3 CASPIAN trial presented at the 2020 American Society of Clinical...
Read MoreNivolumab and Chemo Significantly Improved Survival in ES-SCL
In the phase 2 ECOG-ACRIN EA5161 trial, a significant improvement in both progression-free and overall survival was observed from adding the checkpoint inhibitor nivolumab to chemotherapy (cisplatin/carboplatin with etoposide)...
Read More
New Second-Line Treatment Option for Malignant Pleural Mesothelioma?
To date, second-line chemotherapy is not the standard of care in patients with malignant pleural...
Read More
Conference Highlights: ADA 2020
New research was presented at ADA 2020, the virtual 80th Scientific Sessions of American Diabetes...
Read More